Advertisement

Empagliflozin Approved for Type 2 Diabetes — Physician’s First Watch

Medical News |
August 4, 2014

Empagliflozin Approved for Type 2 Diabetes

By Kelly Young

Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

The FDA has approved empagliflozin (Jardiance) to help patients with type 2 diabetes improve their glycemic control. It is approved for use as a stand-alone or an adjunct treatment.

Empagliflozin is the third sodium glucose co-transporter 2 inhibitor to be FDA approved. It blocks the kidneys' reabsorption of glucose, boosts glucose excretion, and reduces elevated blood glucose levels.

Adverse events associated with empagliflozin include urinary tract infections, female genital infections, and dehydration.

Reader Comments (1)

PAUL HELMAN Physician, Internal Medicine, Northshore University Health Systems

Once again a drug directed at just one element of insulin resistence namely glucose level without addressing the effect on lipid homeostasis which must be kept to the forefront. Diet is basic to control of both. Carbohydrate intolerance is the metabolic nail in the shoe and that nail must be removed rather than walking about with it and treating the consequences.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement